Tag Archives: NervGen Pharma

Vancouver, British Columbia–(Newsfile Corp. – April 9, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today provided a quarterly update with respect to the Company’s previously announced at-the-market equity program (the “ATM Program”) launched on December …

Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI)Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific …

The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024. Vancouver, …

Vancouver, British Columbia–(Newsfile Corp. – March 14, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the “Options”) to employees and consultants of the company, including 100,000 to the company’s officers …

Vancouver, British Columbia–(Newsfile Corp. – March 5, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group and …

Vancouver, British Columbia–(Newsfile Corp. – February 18, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 627,200 incentive stock options to the company’s employees, including 505,200 to the company’s Officers, exercisable at a price of …

Vancouver, Canada–(Newsfile Corp. – January 29, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on …